New Models of Care in the Post-Covid Healthcare World
Observations on models of care in a post-COVID world from HLTH VRTL 2020 with comments on applicability to autoimmune conditions.
Category: autoimmune disease
Dealing with a Rare Eye Disease in the Midst of COVID19
Dealing with a Rare Eye Disease in the Midst of COVID19
After being diagnosed with a rare eye disease, a doctor learns the best treatment is immunosuppression-a risky choice in the midst of COVID19
J&J to buy Momenta Pharmaceuticals for $6.5B
The drugmaker emphasized the full global rights it would acquire to Momenta’s lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.
FDA issues surprise rejection of Gilead, Galapagos rheumatoid arthritis drug
While there had been some risks to filgotinib’s approval cited before, analysts expressed surprise at the decision, with one writing it would likely delay approval by at least a year. Shares of both companies fell sharply on the news.
FDA approves Roche drug for rare autoimmune disorder NMOSD
The agency approved Enspryng for the disease, which is often misdiagnosed as multiple sclerosis and can cause blindness, muscle weakness and paralysis.